Jefferies reiterates Valneva stock Buy rating after Lyme trial data By Investing.com

Valneva's phase III Lyme vaccine narrowly missed the primary per-protocol endpoint with 73.2% efficacy but reached statistical significance on a modified ITT at 74.8%, and Pfizer intends to pursue regulatory filings given efficacy >70%. Shares plunged to $6.49 from $10.49 (~-38%), though Jefferies reiterated a Buy with a $15 PT and analyst targets range $7.50–$18. Valneva beat Q4 2025 estimates: EPS -$0.24 vs -$0.3693 (35.0% surprise) and revenue $55.17M vs $50.56M (9.1% surprise), supporting the view that recent weakness may present a buying opportunity.

Analysis

Market moves are driven more by binary regulatory and narrative signals than by the underlying commercial economics; the real fight will be over label scope, age cohorts and geographic indications rather than headline efficacy. Because the trial was underpowered by lower case counts, regulators will focus on robustness of effect across subgroups and post‑market surveillance commitments — that raises the probability of approval with restrictions or conditional approvals requiring phase IV, not outright rejection.

A Pfizer-led regulatory pathway changes the game: large-cap pharmaceutical involvement materially increases the chances that manufacturing, distribution and payer negotiations will be executed efficiently, shortening time-to-revenue if a label is granted. Second-order winners include contract manufacturers (sterile fill/finish) and established vaccine channels (pediatric/adult immunization programs), while smaller biotech peers may see repriced expectations for what constitutes “acceptable” efficacy in prophylactic vaccines.

Near-term catalysts are discrete and dateable: regulatory filing acceptance, advisory committee scheduling, and any requirement for additional trials or post-approval studies. All are 1–12 month events that will drive >30–50% swings in the equity; longer-term commercial ramp and pricing dynamics (2–5 years) will determine valuation and are subject to payer pushback and potential geographic variability in uptake.

The consensus reaction underestimates two structural outcomes: (1) conditional approval pathways are more likely than full-label approval, which still can create multi-hundred‑million revenue streams; (2) lower disease incidence that hurt trial power will also limit TAM and price elasticity, capping upside absent premium pricing or broad public-health recommendations.

Key Decisions for Investors

• Tactical long VALN (equity): build to 0.3–0.6% NAV on weakness over next 2–6 weeks ahead of expected regulatory filing activity; target a 2.0x return over 9–12 months if filing is accepted and advisory calendar set, stop-loss at -40% from entry or on announcement of a definitive additional trial requirement.
• Options hedge if liquid: buy VALN 9–12 month call spread (long nearer-term ATM call / short higher strike ~30–50% OTM) to cap premium with asymmetric upside; position size sized to risk no more than 0.25% NAV, aiming for 3:1 upside-to-premium if approval/positive label occurs.
• Protective hedge for equity holders: buy 6–9 month puts equal to ~25–35% of net long exposure to cap downside from regulatory negative surprises or dilutive financing; cheaper alternative is put spread to reduce cost.
• Avoid directional trade on PFE for now; instead use it as a funding leg for VALN option structures (covered-call or credit spread) only after regulatory calendar is set — PFE will likely move less on this specific event but can be used to monetize premium if volatility compresses post‑filing.